- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Multiple sclerosis (MS)
- Meeting Date: March 2021
- Public Summary Document (PSD) March 2021 PBAC Meeting - (PDF 1543KB)
- Public Summary Document (PSD) March 2021 PBAC Meeting - (Word 445KB)
Ofatumumab – March 2021
Ofatumumab: Injection 20 mg in 0.4 mL single use pre-filled pen; Kesimpta®
Last updated
2 July 2021